Prostamax (20mg Vial) Dosage Protocol

Overview

Prostamax is a synthetic bioregulator tetrapeptide with the sequence Lys‑Glu‑Asp‑Pro. It is characterized as prostate‑tissue–specific in preclinical literature. Short peptides can interact with DNA and chromatin to influence gene expression programs. Several ultrashort peptides demonstrate cellular uptake via peptide and amino‑acid transporters.

Mechanism of Action

The peptide operates through multiple pathways:

– Gene expression modulation: Short peptides directly interact with nucleosomal DNA and regulatory proteins to modulate transcriptional programs
– Cellular uptake: Ultrashort peptides utilize transporter‑mediated uptake (LAT, PEPT families)
– Immune modulation: Select bioregulator peptides show anti‑inflammatory cytokine modulation, including reduced TNF‑α and IL‑6 signaling

Dosage Protocol

Reconstitution Guide

Standard Approach (3.0 mL → ~6.67 mg/mL):

– Add 3.0 mL bacteriostatic water to the 20 mg vial
– Concentration: approximately 6.67 mg/mL
– On a U‑100 insulin syringe: 1 unit = 0.01 mL ≈ 66.7 mcg
– For doses ≤10 units (≤0.10 mL), consider 30‑ or 50‑unit insulin syringes for improved readability

Dosing Schedule

Gradual Titration Approach:

Administration Details:
– Frequency: Once daily
– Route: Subcutaneous injection
– Duration: 8–12 weeks (optional extension to 16 weeks)
– Suggested dose range: 500–3000 mcg daily with gradual titration
– Timing: Any consistent time of day

Reconstitution Steps

1. Using aseptic technique, draw 3.0 mL bacteriostatic water for injection (multi‑dose diluent with benzyl alcohol)
2. Inject slowly down the vial wall; allow powder to dissolve fully
3. Gently swirl; do not shake
4. Label the vial with contents and reconstitution date
5. Store at 2–8 °C (35.6–46.4 °F); avoid freeze–thaw cycling

Storage Instructions

Lyophilized Vials:
– Keep cold at −20 °C (−4 °F) in dry, dark conditions
– Minimize moisture exposure and light exposure

Reconstituted Solution:
– Refrigerate at 2–8 °C (35.6–46.4 °F)
– Consider aliquoting to minimize freeze–thaw cycles
– Avoid repeated freeze–thaw cycling
– Allow vial to reach room temperature before opening to reduce condensation

Supplies Needed

For 8–16 weeks of once‑daily subcutaneous injections:

Peptide Vials (20 mg each):
– 8 weeks: approximately 5 vials
– 12 weeks: approximately 9 vials
– 16 weeks: approximately 13 vials

Insulin Syringes (U‑100):
– Per week: 7 syringes (1/day)
– 8 weeks: 56 syringes
– 12 weeks: 84 syringes
– 16 weeks: 112 syringes

Bacteriostatic Water (10 mL bottles):
– Uses approximately 3.0 mL per vial
– 8 weeks (5 vials): 15 mL → 2 × 10 mL bottles
– 12 weeks (9 vials): 27 mL → 3 × 10 mL bottles
– 16 weeks (13 vials): 39 mL → 4 × 10 mL bottles

Alcohol Swabs:
– Per week: 14 swabs (one for vial stopper, one for injection site daily)
– 8 weeks: 112 swabs
– 12 weeks: 168 swabs
– 16 weeks: 224 swabs

Injection Technique

Proper Subcutaneous Administration:

– Clean both the vial stopper and injection site with alcohol; allow to dry
– Follow WHO/NCBI aseptic technique guidance
– Pinch the skinfold
– Insert needle at 45° angle into subcutaneous tissue
– Inject slowly and steadily
– Do NOT aspirate for subcutaneous injections
– Remove needle and apply gentle pressure to injection site

Site Rotation:
– Rotate injection sites systematically among: abdomen, thighs, and upper arms
– Rotation minimizes lipohypertrophy and absorption variability
– Avoid repeated injections in the same spot

Potential Benefits

From Preclinical Research:

– Reduced histologic markers of chronic prostatic inflammation in animal models receiving daily parenteral dosing
– Reduced fibrotic markers in prostate tissue
– Mechanistic signals suggest short peptides can influence gene expression and attenuate pro‑inflammatory cytokine signaling
– Potential modulation of immune system inflammatory responses

Note: “Human dosing and clinical efficacy data for Prostamax are limited.”

Tolerability & Side Effects

General Tolerability:
– Subcutaneous injection volumes up to approximately 3.0 mL in the abdomen are generally well tolerated in adults
– Larger volumes may increase injection site discomfort

Local Reactions:
– Mild injection‑site redness, itching, or tenderness may occur
– Lipohypertrophy risk reduced through systematic site rotation
– Tissue irritation minimized by avoiding repeated injections at same location

Safety Considerations:
– New sterile insulin syringes should be used for each injection
– Used syringes must be disposed in an approved sharps container
– No evidence of systemic toxicity in preclinical models at the tested doses

Complementary Lifestyle Factors

– Balanced, protein‑forward nutrition matched to energy needs
– Combination of resistance and aerobic activity to support metabolic health
– Prioritize sleep and stress management for adherence and recovery

Important Notes

– This protocol is intended for research and educational purposes only
– Content does not constitute medical advice, diagnosis, or treatment
– Consult a qualified healthcare professional before beginning any research protocol
– Human clinical efficacy data remain limited; protocol reflects cautious extrapolation from preclinical work
– All information is educational in nature for research purposes only